Study guide
6.3 Pharmacist Prescribing Under Utah Code § 58-17b-627: Tobacco Cessation, HIV PrEP/PEP, Fluoride & Epinephrine
Utah MPJE Pharmacy Jurisprudence Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Utah Pharmacy Regulatory Framework, Facility Licensing & the PIC
1.1 DOPL, the Utah State Board of Pharmacy & the Sources of Utah Pharmacy Law 1.2 Federal vs. Utah Law: Following the Stricter Standard 1.3 Utah Pharmacy License Classes (A–E) & Facility Licensing 1.4 The Pharmacist-in-Charge (PIC): Duties, Self-Audits & Notifications 1.5 Facility Inspections, Ownership & Location Changes, Closing & Facility Discipline
2 Chapter 2: Pharmacist, Intern & Technician Licensure and Personnel
2.1 Pharmacist Licensure, the NAPLEX & Utah MPJE, and Licensure by Endorsement 2.2 License Renewal, Continuing Education & Reinstatement 2.3 Pharmacy Interns & Preceptors 2.4 Pharmacy Technicians, Technician Trainees & Supportive Personnel
3 Chapter 3: Unlawful & Unprofessional Conduct, Discipline, and Impairment
3.1 Unlawful Conduct, Criminal Penalties, Fines & the Disciplinary Process 3.2 Unprofessional Conduct, the APhA Code of Ethics & Utah's Conscience Law 3.3 Impairment, the Utah Professionals Health Program & Reinstatement
4 Chapter 4: Prescription Issuance, Prescriber Authority & Electronic Prescribing
4.1 Prescriber Scope of Authority in Utah 4.2 Required Prescription Elements, Oral & Faxed Orders, and Alterations 4.3 Mandatory Electronic Prescribing of Controlled Substances (EPCS) in Utah 4.4 Legitimate Medical Purpose, Corresponding Responsibility & Red Flags
5 Chapter 5: Patient Counseling, Prospective DUR, Confidentiality & Records
5.1 Patient Counseling: The Offer, Who May Counsel & Delivered Prescriptions 5.2 Prospective Drug Utilization Review & Patient Medication Profiles 5.3 Confidentiality, HIPAA & Protected Health Information 5.4 Pharmacy Records, Retention Periods & Facility Operating Standards
6 Chapter 6: Expanded Practice: Collaboration, Pharmacist Prescribing & Drug Administration
6.1 Collaborative Pharmacy Practice, Drug Therapy Management & Administration of Drugs 6.2 Self-Administered Hormonal Contraception: Standing Order & Pharmacist Prescribing 6.3 Pharmacist Prescribing Under Utah Code § 58-17b-627: Tobacco Cessation, HIV PrEP/PEP, Fluoride & Epinephrine 6.4 Vaccine Administration: DOPL's Protocol, Delegation, Emergencies & USIIS Reporting
7 Chapter 7: Opioid Overdose Prevention, Emergency Refills & Returned or Donated Drugs
7.1 Naloxone & Opioid-Safety Laws in Utah 7.2 Emergency Refills, Combined Refills & Insulin Continuity 7.3 Returned Drugs, Consumer Disposal & the Charitable Prescription Drug Recycling Program
8 Chapter 8: Controlled Substance Schedules, Registration & Security in Utah
8.1 Controlled Substance Schedules: Federal CSA & Utah-Specific Scheduling 8.2 DEA Registration & Facility Licensing 8.3 Controlled Substance Storage & Physical Security
9 Chapter 9: Dispensing Controlled Substances & the Utah Controlled Substance Database
9.1 Schedule II Prescriptions: 30-Day Window, One-Month Supply, Multiple Prescriptions & the 7-Day Acute Limit 9.2 Schedule II Partial Fills, Emergency Oral Orders & Methadone Emergency Orders 9.3 Schedule III–V Prescriptions: Refill Limits, the 80% Rule & Controlled Substance Transfers 9.4 The Utah Controlled Substance Database (CSD)
10 Chapter 10: Dispensing Standards: Labeling, Substitution, Refills, Packaging, Product Integrity & OTC Products
10.1 Prescription Labels: Utah Minimum Elements, Controlled Substance & Opioid Warnings, and Special Labels 10.2 Drug Product Selection: Generic Equivalents, Therapeutically Similar Drugs & Interchangeable Biologics 10.3 Legend-Drug Prescription Validity, Refills & Transfers 10.4 Poison Prevention Packaging Act (PPPA) & Special Packaging 10.5 Drug Product Conditions That Prohibit Dispensing: Adulterated, Misbranded, Outdated, Recalled & Suspect Products 10.6 Nonprescription Products: OTC Labeling & Packaging, Pseudoephedrine, Iodine, Schedule V & Other Restricted OTC Sales
11 Chapter 11: Acquisition, Inventory, Loss, Distribution & Delivery
11.1 Ordering Schedule II Substances: DEA Form 222 & CSOS 11.2 Controlled Substance Inventories & Utah's Schedule II Perpetual Inventory 11.3 Theft, Significant Loss & Disposal of Controlled Substances 11.4 Drug Acquisition & Distribution, Office-Use Sales, and Delivering Prescriptions to Patients
12 Chapter 12: Compounding Standards, USP Chapters & Hazardous Drugs
12.1 Non-Sterile Compounding & USP <795> Standards 12.2 Sterile Compounding & USP <797> Standards 12.3 Hazardous Drug Handling & USP <800> Standards
13 Chapter 13: Institutional, Central Processing, Remote Dispensing, Specialty Outlets & Automation
13.1 Institutional Practice: Hospitals, Pharmaceutical Administration Facilities & Emergency Drug Kits 13.2 Centralized Prescription Processing, Telepharmacy & Remote Dispensing Pharmacies 13.3 Nuclear Pharmacies, Class E Outlets & Dispensing Medical Practitioners 13.4 Automated Pharmacy Systems, Quality Assurance & Pharmacy Audits
6.3 Pharmacist Prescribing Under Utah Code § 58-17b-627: Tobacco Cessation, HIV PrEP/PEP, Fluoride & Epinephrine
Key Takeaways Explain This Topic AI
Since January 1, 2022, a Utah pharmacist may prescribe a drug or device DOPL designates by rule if it is within the pharmacist's training and is not a Schedule I–IV controlled substance (Utah Code § 58-17b-627).
A Utah pharmacist who prescribes under § 58-17b-627 must notify the patient's primary care or other provider within five business days and keep the notification for five years (R156-17b-627(1)(e)).
Under Utah's tobacco cessation guidance, a first prescription may be up to 30 days, total treatment up to 12 weeks, at most twice in a rolling 12 months, with follow-up within 7–21 days.
Utah's tobacco cessation guidance requires the pharmacist to take the patient's blood pressure and to refer patients who are under 18, pregnant or nursing, or have blood pressure over 160/100.
Utah's PEP guidance stresses the 72-hour post-exposure window, and its PrEP guidance allows a 30-day supply when baseline labs are unavailable or a 90-day supply when labs are available.
Last updated: September 2026
6.3 Pharmacist Prescribing Under Utah Code § 58-17b-627: Tobacco Cessation, HIV PrEP/PEP, Fluoride & Epinephrine
The statute (§ 58-17b-627)
Beginning January 1, 2022 , a pharmacist may prescribe a prescription drug or device if:
- it is within the scope of the pharmacist's training and experience ;
- it is designated by DOPL rule ; and
it is not a controlled substance in Schedule I, II, III, or IV (Utah or federal).
A pharmacist is never required to prescribe. DOPL designates drugs starting with public-health concerns identified by DHHS, which the statute lists as HIV PEP, HIV PrEP, self-administered hormonal contraceptives, smoking cessation, naloxone, fluoride, vaccines, and epinephrine. DOPL's rules must include guidelines for notifying the patient's providers and preventing over-prescription (including of antibiotics), and must address when to refer.
General duties when prescribing (R156-17b-627(1))
Prescribing is done from a Class A or Class B pharmacy . Before prescribing, the pharmacist must:
Assess the patient: current health status, past medical history, allergies, medication sensitivities, rationale for care, current medications, and whether to refer.
Follow guidelines from the CDC, nationally accepted sources, and the DHHS/DOPL guidance documents.
Meet the prescription and refill requirements of §§ 58-17b-602 and -609.
Create a follow-up care plan covering monitoring for efficacy and safety, adverse reactions, and further care.
Notify the patient's primary care or other provider within five business days , in writing, electronically, or by phone. If the patient has no provider, give the notification to the patient. The notice must identify the prescribing pharmacist, pharmacy name and phone, patient and date of birth, drug or device, quantity dispensed, directions, refills, and the patient's provider. Keep the notification for five years.
DOPL reviews the guidance documents at least every two years. Currently posted guidance covers tobacco cessation, HIV PrEP and PEP (updated July 31, 2026), naloxone (Section 7.1), self-administered hormonal contraceptives (Section 6.2), fluoride (approved November 18, 2025), and epinephrine.
- Tobacco cessation (Utah Guidance for Smoking Cessation, approved Sept. 28, 2021)
- Screening and referral (care pathway)
Screen Action
Under 18, or pregnant, nursing, or planning either within 6 months Refer to a primary care provider and the Utah Quit Line
- Blood pressure (must be taken by the pharmacist ) If over 160/100 , refer to the PCP and the Quit Line
- Heart attack, arrhythmia, angina, or chest pain in the past two weeks; stomach ulcers Refer (NRT questions)
- Dentures or TMJ / chronic nasal disorder / asthma or COPD Avoid gum / nasal spray / inhaler , respectively
- Eating disorder; seizure, significant head trauma, brain surgery, stroke, or epilepsy Avoid bupropion
Chronic kidney disease, liver disease, or mental illness treated in the past two years Avoid varenicline (and bupropion); refer if the patient still wants it
- MAOI, linezolid, alcohol use, or recent sedative discontinuation Avoid bupropion
- PHQ-2 score of 3 or more Avoid bupropion and varenicline; refer; NRT may be offered
- Any positive suicide screen Immediate referral ; call the PCP (after hours, the crisis line)
Every patient is referred to the Utah Quit Line (1-800-QUIT-NOW) .
Products and dosing highlights
Combination NRT is preferred (a patch plus a short-acting form).
Patch: 21 mg/day if smoking more than 10 cigarettes a day, stepping down to 14 and then 7 mg. 14 mg/day if smoking fewer than 10 a day.
Gum or lozenge: 4 mg if the first cigarette is within 30 minutes of waking, otherwise 2 mg .
Bupropion SR: 150 mg daily for 3 days, then 150 mg twice daily for 8 weeks or longer. Quit day after day 7.
Varenicline: 0.5 mg daily for 3 days, 0.5 mg twice daily for 3 days, then 1 mg twice daily for 12–24 weeks. Quit day after day 7, or up to day 35.
- Prescribing limits
- First prescription: up to 30 days
- Maximum duration: 12 weeks
- Maximum frequency: twice in a rolling 12 months
- Follow-up: documented within 7–21 days (a phone consult is allowed)
- HIV PrEP and PEP (guidance approved July 31, 2026)
PrEP. Anyone who seeks PrEP is eligible, though regimen choice depends on patient factors. Refer (don't prescribe) for hepatitis B infection, HIV infection or reactive or indeterminate HIV testing, creatinine clearance under 30 mL/min, or interacting or nephrotoxic drugs. With labs available, the pharmacist may prescribe 90 days and order the next labs. Without labs, the pharmacist may prescribe 30 days , and the patient must complete the required labs within 30 days. Notify the patient's provider.
PEP. Time-critical: make sure referred patients can be seen within the 72-hour post-exposure window, and keep a low threshold for starting PEP. Preferred regimens follow the CDC 2025 nPEP guidelines. Refer patients with hepatitis B, kidney disease, or hepatic dysfunction. Evaluate hepatitis B immunization, give written notice to the provider, and contact the patient one month after the prescription.
Fluoride and epinephrine
Fluoride (approved Nov. 18, 2025). Systemic fluoride supplements for children ages 3 to 16 at high risk for tooth decay . Dosing depends on the fluoride level of the home water supply, so private wells should be tested first. Counsel on use, adverse effects, fluorosis, storage, and poison control.
Epinephrine. An epinephrine auto-injector for a person 18 or older at risk of anaphylaxis , or a person in a position to assist someone at risk. Before dispensing, the pharmacist must train the recipient on symptoms, calling 911, use, adverse effects, storage, and expiration. Written materials cannot replace this consultation.